Industry News (Joint Venture)

Plans Announced To Develop Cancer Therapies

Published in Vaccine Weekly, September 22nd, 1997

Cytel Corp., San Diego, California, and Searle, Skokie, Illinois, announced plans to collaborate in developing a new class of cancer therapies based on Cytel's proprietary vaccine technology.

Epimmune Inc. has been established to develop therapeutic and prophylactic products for cancer and infectious diseases. The Epimmune technology platform includes Cytel's library of proprietary antigenic epitopes, its proprietary Padre immunostimulant technology and its expertise in epitope discovery and immunology.

"Under the proposed collaboration, Epimmune and Searle intend to focus on the development of Epimmune's cancer technology which allows creation of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1997-09-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry